Genetic breast cancer screening may benefit those at intermediate risk

[News]

Archimedes Inc., a healthcare modeling and analytics company, has announced results of a simulated clinical trial which found that the seven single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was most cost effective when used to guide MRI screenings for patients found to have an intermediate lifetime risk of developing the disease.

More... (http://www.medicalnewstoday.com/releases/269764.php)